This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Williams, J. L. Articles by Rigas, B. Search for Related Content PubMed PubMed Citation Articles by Williams, J. L. Articles by Rigas, B.

Growth Inhibition of Human Colon Cancer Cells by Nitric Oxide (NO)-Donating Aspirin Is Associated with Cyclooxygenase-2 Induction and ß-Catenin/T-Cell Factor Signaling, Nuclear Factor-B, and NO Synthase 2 Inhibition

Implications for Chemoprevention

¹ American Health Foundation Cancer Center, Institute for Cancer Prevention, Valhalla, New York;
² Sarah C. Upham Division of Gastroenterology, New York Medical College, Valhalla, New York;
³ Department of Physiology and Pharmacology, City University of New York Medical School, New York, New York;
⁴ Chemoprevention Branch, National Cancer Institute, NIH, Bethesda, Maryland

Nitric oxide (NO)-releasing aspirin (ASA), consisting of a traditional ASA molecule to which a NO-donating moiety is covalently bound, is a promising colon cancer chemopreventive agent. NO-ASA inhibits colon cancer cell growth more potently than ASA by inhibiting cell proliferation and enhancing cell killing. We examined in cultured human colon cancer cells the effect of NO-ASA on the ß-catenin/T-cell factor signaling pathway, nuclear factor-B, and NO synthase 2 and on cyclooxygenase (COX) expression, all presumed to participate in colon carcinogenesis. Besides inhibiting cell growth, NO-ASA inhibited the ß-catenin/T-cell factor signaling pathway (IC₅₀, 1.1 µM), nuclear factor-B DNA binding (IC₅₀, 7.5 µM), and NO synthase 2 expression (IC₅₀, 2 µM). Interestingly, NO-ASA induced COX-2 expression, although it had no effect on COX-1. COX-2 induction was accompanied by increased prostaglandin E₂ production. These effects occurred at NO-ASA concentrations below or near its IC₅₀ for cell growth (IC₅₀, 2–50 µM). The metabolism of NO-ASA by these cells is characterized by a rapid deacetylation step and the formation of a conjugate with glutathione. NO-ASA had no effect on intracellular cyclic GMP concentrations. We propose a model incorporating the pleiotropic effects of NO-ASA on cell signaling and postulate that collectively these effects may contribute to its strong chemopreventive effect.

This article has been cited by other articles:

				J. L. Williams, P. Ji, N. Ouyang, X. Liu, and B. Rigas NO-donating aspirin inhibits the activation of NF-{kappa}B in human cancer cell lines and Min mice Carcinogenesis, February 1, 2008; 29(2): 390 - 397. [Abstract] [Full Text] [PDF]

				M. A. McIlhatton, J. Tyler, S. Burkholder, J. Ruschoff, B. Rigas, L. Kopelovich, and R. Fishel Nitric Oxide Donating Aspirin Derivatives Suppress Microsatellite Instability in Mismatch Repair Deficient and Hereditary Nonpolyposis Colorectal Cancer Cells Cancer Res., November 15, 2007; 67(22): 10966 - 10975. [Abstract] [Full Text] [PDF]

				G. K. Hagos, R. E. Carroll, T. Kouznetsova, Q. Li, V. Toader, P. A. Fernandez, S. M. Swanson, and G. R.J. Thatcher Colon cancer chemoprevention by a novel NO chimera that shows anti-inflammatory and antiproliferative activity in vitro and in vivo Mol. Cancer Ther., August 1, 2007; 6(8): 2230 - 2239. [Abstract] [Full Text] [PDF]

				K. H. Choi, M. W. Park, S. Y. Lee, M.-Y. Jeon, M. Y. Kim, H. K. Lee, J. Yu, H.-J. Kim, K. Han, H. Lee, et al. Intracellular expression of the T-cell factor-1 RNA aptamer as an intramer. Mol. Cancer Ther., September 1, 2006; 5(9): 2428 - 2434. [Abstract] [Full Text] [PDF]

				H.-Y. Tang, A. Shih, H. J. Cao, F. B. Davis, P. J. Davis, and H.-Y. Lin Resveratrol-induced cyclooxygenase-2 facilitates p53-dependent apoptosis in human breast cancer cells. Mol. Cancer Ther., August 1, 2006; 5(8): 2034 - 2042. [Abstract] [Full Text] [PDF]

				C. V. Rao, B. S. Reddy, V. E. Steele, C-X Wang, X. Liu, N. Ouyang, J. M.R. Patlolla, B. Simi, L. Kopelovich, and B. Rigas Nitric oxide-releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets. Mol. Cancer Ther., June 1, 2006; 5(6): 1530 - 1538. [Abstract] [Full Text] [PDF]

				N. Ouyang, J. L. Williams, G. J. Tsioulias, J. Gao, M. J. Iatropoulos, L. Kopelovich, K. Kashfi, and B. Rigas Nitric oxide-donating aspirin prevents pancreatic cancer in a hamster tumor model. Cancer Res., April 15, 2006; 66(8): 4503 - 4511. [Abstract] [Full Text] [PDF]

				J. Gao, K. Kashfi, X. Liu, and B. Rigas NO-donating aspirin induces phase II enzymes in vitro and in vivo Carcinogenesis, April 1, 2006; 27(4): 803 - 810. [Abstract] [Full Text] [PDF]

				J. J. Turchi Nitric oxide and cisplatin resistance: NO easy answers PNAS, March 21, 2006; 103(12): 4337 - 4338. [Full Text] [PDF]

				B. Rigas and K. Kashfi Cancer Prevention: A New Era beyond Cyclooxygenase-2 J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 1 - 8. [Abstract] [Full Text] [PDF]

				C. De Santo, P. Serafini, I. Marigo, L. Dolcetti, M. Bolla, P. Del Soldato, C. Melani, C. Guiducci, M. P. Colombo, M. Iezzi, et al. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination PNAS, March 15, 2005; 102(11): 4185 - 4190. [Abstract] [Full Text] [PDF]